Brainsway Ltd · TASE:BWAY

Brainsway — Investor Presentation (2016)

33 slides from Brainsway's investor presentation, 2016

1. Slide 1: Deep Transcranial Magnetic Stimulation

   ‫בס"ד‬ TASE:BRIN Deep Transcranial Magnetic Stimulation

2. Slide 2: Disclaimer

   ‫בס"ד‬ TASE:BRIN Disclaimer • THIS PRESENTATION OF BRAINSWAY LTD. (“BRAINSWAY”) DOES NOT PURPORT TO BE ALL-INCLUSIVE OR TO CONTAIN INFORMATION PERTAINING TO THE SUBJECT MATTER HEREOF AND MAY NOT BE RELIED UPON FOR MAKING ANY COLLABORATION DECISION WITH RESPECT TO BRAINSWAY. • THE INFORMATION PROVIDE

3. Slide 3: Agenda for Discussion

   TASE:BRIN Agenda for Discussion 1 Introduction 2 Deep TMS Technology 3 Major Depression, Proven Efficacy and Safety with Superior Results 4 Major Depression, Business Opportunity 5 Growth Strategy and Execution Plan 6 Summary 3 Deep TMS

4. Slide 4: Brainsway Snapshot

   ‫בס"ד‬ TASE:BRIN Brainsway Snapshot The need & technology Mental illness is widespread and Pharmacotherapy for brain Deep TMS: a unique patented undertreated disorders is often therapeutic neuromodulatory Deep TMS: Highly effective inadequate modality treatment Platform FDA cleared for depression Br

5. Slide 5: Our Vision

   ‫בס"ד‬ TASE:BRIN Our Vision To be the global leader in non-invasive brain disorder therapy Deep TMS

6. Slide 6: Management Team

   ‫בס"ד‬ TASE:BRIN Management Team David Zacut, MD Chairman of the Board and acting CEO Dr. Zacut has served as Brainsway's Chairman of the Board of Directors since the company's inception, and has been providing consulting services to Brain Research Services since May 2001. Since 1983, Dr. Zacut has

7. Slide 7: Major Depression Disorder (MDD), A Huge Unmet Need

   TASE:BRIN ‫בס"ד‬ Major Depression Disorder (MDD), A Huge Unmet Need Very high prevalence In any given year there are 15 million Americans who suffer a major depressive episode US depression A clear unmet need Fail to respond to 1st Current drug treatment is therapeutics line treatment Fail to achiev

8. Slide 8: Agenda for Discussion

   ‫בס"ד‬ TASE:BRIN Agenda for Discussion 1 Introduction 2 Deep TMS Technology 3 Major Depression, Proven Efficacy and Safety with Superior Results 4 Major Depression, Business Opportunity 5 Growth Strategy and Execution Plan 6 Summary 3 Deep TMS

9. Slide 9: Treatment Options for Treatment Resistant Depression (TRD)

   TASE:BRIN ‫בס"ד‬ Treatment Options for Treatment Resistant Depression (TRD) Electroconvulsive therapy (ECT)  Effective  Rapid onset  Requires hospitalization and anesthesia  Severe side effects (memory loss, nausea, mood changes and headaches)  Negative stigma attached Electroconvulsive therapy

10. Slide 10: Brainsway Deep TMS Technology

    TASE:BRIN ‫בס"ד‬ Brainsway Deep TMS Technology 1 Rapidly changing electric field in the brain, leading to axonal depolarization and action potentials. 2 Brainsway proprietary coils optimize TMS therapy and allow for deep stimulation of the brain. 3 The deeper and broader field produced by the H1-coi

11. Slide 11: fMRI Demonstrates Superiority of Deep TMS

    ‫בס"ד‬ TASE:BRIN fMRI Demonstrates Superiority of Deep TMS Figure-8 effect on task-related activation (relative to sham) Deep TMS effect on task-related activation (relative to sham) Deep TMS modulates task-related activity to a greater degree than either figure-8 or sham coils. Importantly, this mo

12. Slide 12: Deep TMS Procedure and Platform System

    TASE:BRIN ‫בס"ד‬ Deep TMS Procedure and Platform System Non-invasive No anesthesia Well-tolerated Each treatment session lasts approximately 20 minutes Typical treatment protocol: 4 weeks of 3-5 sessions per week Platform technology for a variety of indications Deep TMS

13. Slide 13: Agenda for Discussion

    ‫בס"ד‬ TASE:BRIN Agenda for Discussion 1 Introduction 2 Deep TMS Technology 3 Major Depression, Proven Efficacy and Safety with Superior Results 4 Major Depression, Business Opportunity 5 Growth Strategy and Execution Plan 6 Summary 3 Deep TMS

14. Slide 14: Brainsway MDD Multicenter Trial

    TASE:BRIN ‫בס"ד‬ Brainsway MDD Multicenter Trial  Double-blind, randomized, controlled study Trial Protocol Acute Treatment for the treatment of Major Depressive 5 sessions per week 4 weeks Disorder (MDD) Maintenance  22 medical centers worldwide 2 sessions per week 12 weeks  212 treatment-resist

15. Slide 15: Major Depression – 4-Week Acute Treatment Followed by 18-Week Maintenance Therapy

    TASE:BRIN Major Depression– 4-Week Acute Treatment ‫בס"ד‬ Followed by 18-Week Maintenance Therapy The trial protocol Sessions per week Weeks 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Results 90% 80% 81.1% 70% 71.6% 60% response Response 50% remmision 46.2% 40% Remission 30% 26.9% 20%

16. Slide 16: Agenda for Discussion

    ‫בס"ד‬ TASE:BRIN Agenda for Discussion 1 Introduction 2 Deep TMS Technology 3 Major Depression, Proven Efficacy and Safety with Superior Results 4 Major Depression, Business Opportunity 5 Growth Strategy and Execution Plan 6 Summary 3 Deep TMS

17. Slide 17: Everybody Wins

    ‫בס"ד‬ TASE:BRIN Everybody Wins Patients Physicians Researchers Insurance MDD patients are Healthcare Brainsway’s research Deep TMS treatment getting the best professionals are able activities. Four multi- reduces direct and treatment with a rapid to treat their patients center studies as well as in

18. Slide 18: Over 240 Million Covered Lives in US

    ‫בס"ד‬ TASE:BRIN Over 240 Million Covered Lives in US Insurance Coverage of TMS Depression Therapy Over 85% of US population 75% of Medicare beneficiaries Deep TMS

19. Slide 19: Reimbursement Is Past The Tipping Point

    ‫בס"ד‬ TASE:BRIN Reimbursement Is Past The Tipping Point Deep TMS

20. Slide 20: How Do We Partner?

    TASE:BRIN How Do We Partner ? ‫בס"ד‬ Customer’s Lease Buy perspective Cost per procedure Minimal (patient cap) Minimal (patient cap) Procedures/Sessions Unlimited Unlimited Cost of device Annual lease One time purchase Service Included Included only for 1st year Brainsway’s objective: Penetrate the

21. Slide 21: Agenda for Discussion

    ‫בס"ד‬ TASE:BRIN Agenda for Discussion 1 Introduction 2 Deep TMS Technology 3 Major Depression, Proven Efficacy and Safety with Superior Results 4 Major Depression, Business Opportunity 5 Growth Strategy and Execution Plan 6 Summary 3 Deep TMS

22. Slide 22: Transforming Brainsway

    ‫בס"ד‬ TASE:BRIN Transforming Brainsway Sustain superiority New indications ,Dual Channel, New breakthrough neuromodulation technologies Grow sales & penetrate key markets Focus commercial efforts on MDD in main markets From ‘start-up’ to growth Establish Processes, Efficiency, Build commercial expe

23. Slide 23: Recent Commercial Efforts, Showing to be Effective

    ‫בס"ד‬ TASE:BRIN Recent Commercial Efforts, Showing to be Effective  Shifted focus from R&D to a balanced approach with greater emphasis on sales & marketing  Focus on main approved indication – MDD  Established US HQ & Went direct  New management team  Hired additional field personnel  Drivin

24. Slide 24: Why Stop At Depression?

    ‫בס"ד‬ TASE:BRIN Why Stop At Depression? Alzheimer’s - PFC PTSD - PFC Smoking & Alcohol - Insula Psychiatry ADHD - PFC Neurology Parkinson's disease - PFC, MDD - DLPFC MC MCI- PCC Autism - Medial PFC Multiple sclerosis - MC Bipolar disorder - PFC OCD - ACC Schizophrenia - PFC Epilepsy - Temporal cor

25. Slide 25: A Strong and Diverse Clinical Pipeline

    ‫בס"ד‬ TASE:BRIN A Strong and Diverse Clinical Pipeline Observed Clinical Outcome Deep TMS

26. Slide 26: 5-year Project Timeline

    ‫בס"ד‬ TASE:BRIN 5-year Project Timeline Clinical Studies Multicenter trial, under FDA guidelines Interim analysis OCD N=98 FDA evaluation/approval/launch Smoking Cessation N=235 (Interim=62) PTSD N=166 (Interim=80) Bipolar Depression N=236 2016 2017 2018 2019 2020 Jan Jul Deep TMS

27. Slide 27: Strong R&D Pipeline

    ‫בס"ד‬ TASE:BRIN Strong R&D Pipeline Ch1: High Ch2: Low • Multi-channel stimulator frequency (facilitation) frequency (inhibition) • Breakthrough in TMS treatment • Patent-protected • Allows treatment of the most complicated brain disorders • Combined synchronized differential activation of differen

28. Slide 28: Brainsway's 4-Tiered Expansion Model

    TASE:BRIN Brainsway’s 4-Tiered Expansion Model ‫בס"ד‬ TMS Centers 2030 , drug addiction, alcoholism, gambling addiction Brain Drug Delivery Blood-brain barrier opening Neurology , , , , , autism & Asperger’s, epilepsy, migraine, tinnitus, blepharospasm Psychiatry , , , , schizophrenia, ADHD, Tourett

29. Slide 29: Agenda for Discussion

    ‫בס"ד‬ TASE:BRIN Agenda for Discussion 1 Introduction 2 Deep TMS Technology 3 Major Depression, Proven Efficacy and Safety with Superior Results 4 Major Depression, Business Opportunity 5 Growth Strategy and Execution Plan 6 Summary 3 Deep TMS

30. Slide 30: Balance Sheet – As of September 30, 2015

    TASE:BRIN ‫בס"ד‬ Balance Sheet – As of September 30, 2015 Balance Sheet • Cash Balance - NIS 49M Consolidated Statements of Financial Position • Current Assets - NIS 60M As of September December 30, 31, (NIS in thousands) 2015 2014 Cash and cash equivalents 45,390 67,130 Short-term deposits 4,262 4,

31. Slide 31: Financial Statements – As of September 30, 2015

    TASE:BRIN ‫בס"ד‬ Financial Statements – As of September 30, 2015 Income Statements 9 months period ended 3 months period ended Year ended September September September September December June 30, 30, 30, 30, 30, 31, (NIS in thousands) 2015 2014 % 2015 2014 % 2015 % 2014 Revenues 17,669 8,049 120% 7,

32. Slide 32: Highlights

    ‫בס"ד‬ TASE:BRIN Highlights  Proven and proprietary Deep TMS technology  FDA clearance and reimbursement (>70% of US population) for major depressive disorder  Compelling business model  Commercial team in place to capitalize on the growing MDD Deep TMS opportunity  Healthy quarter-over-quarter

33. Slide 33: Deep TMS Remission Accomplished

    TASE:BRIN ‫בס"ד‬ Deep TMS Remission Accomplished

Brainsway — Investor Presentation (2016) on 6ix